Key Performance
More- Earnings Score: 60
- Momentum Score: 37
- True Yield: N/A
- Financial Health Score: 100
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals reported first quarter 2026 XDEMVY net product sales exceeding $145 million, representing an 85% year-over-year increase. The company reaffirmed its full-year 2026 guidance of $670-700 million in XDEMVY sales and announced participation in three upcoming investor conferences in May.
05/07/2026, 5:00 PM • GlobeNewswire
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade
Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares worth approximately $839,000 between March 17-19, 2026. The sale was a non-discretionary, tax-withholding-driven transaction tied to RSU vesting rather than a reflection of insider sentiment. Despite the insider sale, the company continues to show strong commercial execution with $451.4 million in net product sales in 2025 (more than double the prior year), driven by rapid adoption of XDEMVY, with gross margins around 93% and narrowing net losses.
03/24/2026, 1:06 PM • The Motley Fool
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Tarsus Pharmaceuticals will host a live webcast on November 4, 2025, to report its third quarter 2025 financial results and provide a corporate update. The company has FDA-approved XDEMVY for Demodex blepharitis and is developing additional treatments for eye care and infectious disease prevention.
10/28/2025, 5:00 PM • GlobeNewswire
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.
10/27/2025, 11:15 AM • The Motley Fool
DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.
10/01/2025, 1:00 PM • GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals plans to participate in two upcoming healthcare investment conferences in September 2025, showcasing its eye care and infectious disease prevention pipeline, including its FDA-approved XDEMVY® treatment for Demodex blepharitis.
08/27/2025, 5:00 PM • GlobeNewswire
3 Biotech Catalysts Present Major Opportunity
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
08/27/2025, 4:26 AM • Investing
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Tarsus Pharmaceuticals will host a live webcast on August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update, discussing its eye care and infectious disease prevention pipeline.
07/30/2025, 5:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.